This copy is for your personal, non-commercial use only. To order presentation-ready copies for distribution to your colleagues, clients or customers visit http://www.djreprints.com.

https://www.barrons.com/articles/provention-bio-stock-sanofi-acquisition-7f5a2c9d

Provention Bio Stock Soars on $2.9 Billion Acquisition by Sanofi

By
Joe Woelfel
  • Order Reprints
  • Print Article

Shares of Provention Bio soared Monday after the biopharmaceutical company agreed to be acquired by France’s Sanofi (SNY) for $25 a share, or about $2.9 billion.

Provention Bio (ticker: PRVB), which focuses on autoimmune diseases, jumped 260% to $24.14 in premarket trading Monday. The stock closed Friday at $6.70. American depositary receipts of Sanofi fell 0.3%.

Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved

This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com.